Peak Veterinary Referral Center
  • Phone: 802-878-2022
  • Our Services
    • Behavior
    • Cardiology
    • Dermatology
    • Diagnostic Imaging
    • Internal Medicine
    • Oncology
    • Ophthalmology
    • Surgery
  • For Your Pet
    • Client Registration Form
    • COVID Curb-Side Procedures
    • When Your Pet is a Patient
    • Clinical Studies
    • Pet Insurance
    • Grief Resources
  • For Veterinary Teams
    • COVID-19 Hospital Updates
    • Referral Forms and Portal
    • Clinical Studies
    • VetBloom
    • Continuing Education
    • Contact Us
  • About Us
    • Our Hospital
    • Our Team
    • Why Ethos
    • Contact Us
  • Our Blogs
  • We’re Hiring!
    • Apply Today
    • Benefits and Perks
    • Vet Student Externships
    • Candidate Competencies
    • Continuing Education
Peak Veterinary Referral Center
  • Our Services
    • Behavior
    • Cardiology
    • Dermatology
    • Diagnostic Imaging
    • Internal Medicine
    • Oncology
    • Ophthalmology
    • Surgery
  • For Your Pet
    • Client Registration Form
    • COVID Curb-Side Procedures
    • When Your Pet is a Patient
    • Clinical Studies
    • Pet Insurance
    • Grief Resources
  • For Veterinary Teams
    • COVID-19 Hospital Updates
    • Referral Forms and Portal
    • Clinical Studies
    • VetBloom
    • Continuing Education
    • Contact Us
  • About Us
    • Our Hospital
    • Our Team
    • Why Ethos
    • Contact Us
  • Our Blogs
  • We’re Hiring!
    • Apply Today
    • Benefits and Perks
    • Vet Student Externships
    • Candidate Competencies
    • Continuing Education
  • Phone: 802-878-2022
802-878-2022     |     158 Hurricane Lane, Williston, VT 05495

Sorafenib for the Treatment of Solid Tumors in Dogs

Sorafenib for the Treatment of Solid Tumors in Dogs

No Longer Enrolling

de novo study

Description

Sorafenib is a cancer treatment that has been approved for use in human renal cell carcinoma and hepatocellular carcinoma. It has a distinctive inhibitory activity that may be especially valuable at preventing the harmful resistance mechanism known as “evasive resistance” (the promotion of metastasis despite drug activity against the primary tumor). We have previously reported on the tolerability and hints of clinical activity of Sorafenib in dogs with cancer. This background provides a rationale for the further study of Sorafenib in dogs with cancer. In this study we seek to define an optimal dosing schedule for Sorafenib and will assess its tolerability and activity in dogs with solid tumors.

Eligibility criteria

  • Any dog with a history of cancer that has a measurable solid tumor
  • Dogs that weigh >5kg and <45kg

Participating hospitals

  • Massachusetts Veterinary Referral Hospital, Woburn, MA
  • Peak Veterinary Referral Center, Williston, VT
  • Port City Veterinary Referral Hospital, Portsmouth, NH
  • The Oncology Service, Richmond, VA
  • The Oncology Service, Springfield, VA
  • WVRC – Waukesha, WI

Interested?

Enroll or request more information below

Share

Frequently Asked Questions

  • Clinical Studies
Peak Veterinary Referral Center
802-878-2022 | 158 Hurricane Ln, Williston, VT 05495
  • Phone: 802-878-2022
  • Our Services
    • Behavior
    • Cardiology
    • Dermatology
    • Diagnostic Imaging
    • Internal Medicine
    • Oncology
    • Ophthalmology
    • Surgery
  • For Your Pet
    • Client Registration Form
    • COVID Curb-Side Procedures
    • When Your Pet is a Patient
    • Clinical Studies
    • Pet Insurance
    • Grief Resources
  • For Veterinary Teams
    • COVID-19 Hospital Updates
    • Referral Forms and Portal
    • Clinical Studies
    • VetBloom
    • Continuing Education
    • Contact Us
  • About Us
    • Our Hospital
    • Our Team
    • Why Ethos
    • Contact Us
  • Our Blogs
  • We’re Hiring!
    • Apply Today
    • Benefits and Perks
    • Vet Student Externships
    • Candidate Competencies
    • Continuing Education
© 2021 Peak Veterinary Referral Center
Website Design by Jackrabbit